Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Therapeutic Advances in Urology|September 10, 2011
An update on the use of gonadotropin-releasing hormone antagonists in prostate cancerLaurent Boccon-Gibod, Egbert van der Meulen, Bo-Eric Persson
The Journal of Urology|September 28, 2011
Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelixMatthew R Smith, Laurence Klotz, Egbert van der Meulen, et al.
Endocrine|March 23, 2016
Delaying time to first nocturnal void may have beneficial effects on reducing blood glucose levelsKristian Vinter Juul, Niels Jessen, Donald L Bliwise, et al.
BJU International|November 19, 2016
Low-dose desmopressin combined with serum sodium monitoring can prevent clinically significant hyponatraemia in patients treated for nocturiaKristian Vinter Juul, Anders Malmberg, Egbert van der Meulen, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 20, 2014
The Nocturia Impact Diary: a self-reported impact measure to complement the voiding diaryTove Holm-Larsen, Fredrik Andersson, Egbert van der Meulen, et al.
International Journal of Psychiatry in Clinical Practice|June 12, 2014
Treating depression with different galenical drug formulations: Does it make a difference? The comparison of mirtazapine fast dissolving formulation (FDT) with conventional mirtazapine tablets (CT)Alexandra Delini-Stula, Helga van Oers, Arjen van Willigenburg, et al.
Sleep Health|October 27, 2017
Delay of first voiding episode is associated with longer reported sleep durationDonald L Bliwise, Tove Holm-Larsen, Sandra Goble, et al.
The Journal of Clinical Psychiatry|March 4, 2009
Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patientsArmin Szegedi, Wim T Jansen, Arjen P P van Willigenburg, et al.
Urologia Internationalis|December 22, 2012
Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233)John Anderson, Ghandi Al-Ali, Manfred Wirth, et al.
Urology|July 4, 2012
The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patientsJan-Erik Damber, Teuvo L J Tammela, Peter Iversen, et al.
Pageof 2